BioArctic AB (OTCPK:BRCTF)
$ 15.76 -0.0368 (-0.23%) Market Cap: 1.37 Bil Enterprise Value: 1.32 Bil PE Ratio: 0 PB Ratio: 14.20 GF Score: 58/100

Q4 2023 BioArctic AB Earnings Call Transcript

Feb 14, 2024 / 08:30AM GMT
Release Date Price: $19.03
Operator

Welcome to BioArctic Q4 report 2023 for the first part of the conference call. (Operator Instructions) Now I will hand the conference over to CEO, Gunilla Osswald; and CFO, Anders Martin-Löf, please go ahead.

Gunilla Osswald;publ;CEO
BioArctic AB

()-

Good morning, and welcome to buy BioArctic presentation for the fourth quarter and for the full year of 2023 I'm Gunilla Osswald and I'm CEO of BioArctic, and I will share today's presentation with our CFO, Anders Martin-Löf.

It's very exciting times to BioArctic with lecanemab being the first and only disease-modifying treatment with a full approval in the US and Japan and now also in China, it's the beginning of a new era and BioArctic is behind this true breakthrough in the treatment of Alzheimer's disease. I find it extremely gratifying that we now can help a large number of patients and their families, and I'll talk more about that here today.

Next slide, please. BioArctic is listed at Nasdaq, Stockholm, Large-Cap, and this is our disclaimer.

Next

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot